Risultati per: La FDA approva il sistema di riabilitazione dell’ictus

In late February, the US Food and Drug Administration (FDA) granted an Emergency Use Authorization to an at-home diagnostic test that identifies SARS-CoV-2, the virus that causes COVID-19, as well as influenza strains A and B. The test detected 100% of negative and 88.3% of positive COVID-19 samples, 99.3% of negative and 90% of positive influenza A samples, and 99.9% of negative influenza B samples.

La campagna mondiale dal 13 al 19 marzo

New England Journal of Medicine, Ahead of Print.

Per gli adulti, agisce in 15 minuti su dolore e altri sintomi

The US Food and Drug Administration (FDA) has approved the first oral treatment for anemia caused by chronic kidney disease.

This study examines the Food and Drug Administration’s accelerated approval pathway and whether preapproval initiation was associated with faster conversion to traditional approval or withdrawal for drugs with nononcology indications.

La terapia cellulare per il trattamento del glioblastoma multiforme, tumore cerebrale molto aggressivo, rappresenta un cambio di paradigma nell’approccio a una malattia che a oggi non ha una cura

This quality improvement study identifies adverse events for inferior vena cava filters and reports changes in adverse event reporting and estimated insertions between 2016 and 2020 in the US.

The US Food and Drug Administration (FDA) has announced proposed changes in its recommendations governing blood donor eligibility to reduce the risk of transfusion-transmitted HIV. The proposed guidance assesses risk using gender-inclusive, individual questionnaires rather than using broad time-based deferrals.

E’ un tampone nasale, risultati in 30 minuti

New England Journal of Medicine, Ahead of Print.

In sviluppo per tipo episodico,piattaforma e app contro attacchi

A treatment that may moderately slow mild cognitive decline and reduce amyloid-β plaques in patients with early Alzheimer disease gained accelerated approval from the US Food and Drug Administration (FDA). Lecanemab-irmb, marketed as Leqembi by Eisai and Biogen, is indicated for patients with mild cognitive impairment or mild dementia due to Alzheimer disease.